Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

MLA

Salvatore Siena, et al. “Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer.” PLoS ONE, vol. 8, no. 11, Jan. 2013, p. e62264. EBSCOhost, https://doi.org/10.1371/journal.pone.0062264.

APA

Salvatore Siena, Eric Van Cutsem, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Katia Bencardino, Maria Elena Elez, Hans Prenen, Mireia Sanchis, Andrea Sartore-Bianchi, Sabine Tejpar, Anita Gandhi, Tao Shi, & Josep Tabernero. (2013). Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS ONE, 8(11), e62264. https://doi.org/10.1371/journal.pone.0062264

Chicago

Salvatore Siena, Eric Van Cutsem, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Katia Bencardino, et al. 2013. “Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer.” PLoS ONE 8 (11): e62264. doi:10.1371/journal.pone.0062264.